Imcivree

Chemical Namesetmelanotide
Dosage FormInjection (subcutaneous; 10 mg/mL)
Drug ClassReceptor agonists
SystemEndocrine
CompanyRhythm Pharmaceuticals, Inc.
Approval Year2020

Indication

  • For chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.
Last updated on 12/18/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Imcivree (setmelanotide) Prescribing Information. 2020Rhythm Pharmaceuticals, Inc. Boston, MA